Abstract 11972: Venous Thromboembolism Recurrence Rate and Risk Factors in a European Population
Introduction: This study estimated venous thromboembolism (VTE) recurrence and risk factors in a European population, given limited data in this region.
Methods: This retrospective cohort study included data collected from physicians recruited from an online panel in France, Spain, Italy, and Germany. Physicians completed case report forms for the next 3-4 patients seen in consultation for any reason who had an initial VTE event in the prior 3 to 24 months (i.e., patients who survived 90 days since their initial VTE). Included were 376 general practitioners and 307 specialists, providing 2,184 patient records and information on patient demographics, comorbidities, and VTE recurrence. Kaplan-Meier estimation provided cumulative incidence survival functions accounting for censored data (patient records varied from 3-24 months post-initial VTE). Risk factors for VTE were assessed.
Results: Patients’ mean age was 61.3 years (SD=14.3) and 47.4% were female. Of 2,184 patients, 379 developed recurrent VTE over 1,298 person-years of follow-up. The table shows cumulative incidence of VTE in the overall population and by risk categories. The 6-month cumulative incidence of VTE recurrence was 11.7%; the 12-month cumulative incidence was 27.6%. VTE cumulative incidence did not differ by age, gender or initial VTE type. However, it was higher in patients with moderate-to-strong vs. weak Anderson & Spencer summary risk scores (p=.001); e.g., 12-month rates of 33.8%, vs. 20.9%, respectively.
Conclusions: VTE recurrence is high in this European population and increases with time since initial VTE event, suggesting the need for targeted anticoagulant treatment following an initial VTE event and longer term prevention of VTE recurrence. Among risk factors investigated, Anderson & Spencer scores help differentiate patients more likely to experience recurrence within 12 months of initial VTE.
Author Disclosures: M. Hamilton: Employment; Significant; BMS funded the current study. A. Goren: Consultant/Advisory Board; Significant; Kantar Health conducted the study with funding from BMS. S. Gupta: Consultant/Advisory Board; Significant; Kantar Health conducted the study with funding from BMS. S. Auziere: Consultant/Advisory Board; Significant; Kantar Health conducted the study with funding from BMS. A. Claflin: Consultant/Advisory Board; Significant; Pfizer conducted the study with funding from BMS. H. Phatak: Employment; Significant; BMS funded the current study.
- © 2014 by American Heart Association, Inc.